<code id='C76075CCF9'></code><style id='C76075CCF9'></style>
    • <acronym id='C76075CCF9'></acronym>
      <center id='C76075CCF9'><center id='C76075CCF9'><tfoot id='C76075CCF9'></tfoot></center><abbr id='C76075CCF9'><dir id='C76075CCF9'><tfoot id='C76075CCF9'></tfoot><noframes id='C76075CCF9'>

    • <optgroup id='C76075CCF9'><strike id='C76075CCF9'><sup id='C76075CCF9'></sup></strike><code id='C76075CCF9'></code></optgroup>
        1. <b id='C76075CCF9'><label id='C76075CCF9'><select id='C76075CCF9'><dt id='C76075CCF9'><span id='C76075CCF9'></span></dt></select></label></b><u id='C76075CCF9'></u>
          <i id='C76075CCF9'><strike id='C76075CCF9'><tt id='C76075CCF9'><pre id='C76075CCF9'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:7495
          Jennifer Doudna Feng Zhang CRISPR
          CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

          The revolution started in silence.

          Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

          advertisement

          No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Wegovy trial has doctors encouraged over new possibilities

          AdobeThemomentumaroundweightlossdrugsisabouttogetevenbiggerinthewakeofNovoNordisk’sannouncementthati